BTN2A3P: A Potential Drug Target and Biomarker (G54718)

Target Name: BTN2A3P

NCBI ID: G54718

BTN2A3P

Other Name(s): Butyrophilin subfamily 2 member A3, pseudogene | BTN2.3 | butyrophilin subfamily 2 member A3, pseudogene | BTN2A3

BTN2A3P: A Potential Drug Target and Biomarker

Blood Pressure (BP) is a major risk factor for cardiovascular disease, and it is a condition that affects millions of people worldwide. The second-largest cause of death worldwide is cardiovascular disease, which includes heart failure, coronary artery disease, and stroke. As a result, it is important to identify potential drug targets and biomarkers for treating hypertension. BTN2A3P is one such potential drug target and biomarker that has gained significant interest in recent years.

BTN2A3P is a protein that is expressed in the brain and is known to play a role in the regulation of blood pressure. The BTN2A3P gene has been shown to be involved in the regulation of blood pressure by controlling the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a hormonal system that helps to regulate blood pressure by controlling the production of angiotensin II, a hormone that increases blood pressure.

Studies have shown that BTN2A3P is involved in the regulation of blood pressure by controlling the activity of the RAAS. When angiotensin II is produced, it causes the blood vessels to constrict and blood pressure to rise. However, when BTN2A3P is activated, it inhibits the activity of the RAAS and reduces the production of angiotensin II. This has the potential to lower blood pressure, making it a potential drug target for treating hypertension.

BTN2A3P has also been shown to be involved in the regulation of blood pressure by controlling the activity of the nervous system. The nervous system plays a critical role in regulating blood pressure by controlling the contraction and dilation of blood vessels. Studies have shown that BTN2A3P is involved in the regulation of the nervous system by controlling the activity of a protein called P2Y12. P2Y12 is a receptor that is involved in the regulation of blood pressure and has been shown to be involved in the development of hypertension.

In addition to its potential role in the regulation of blood pressure, BTN2A3P has also been shown to be involved in the regulation of blood pressure by controlling the production of another hormone called nitric oxide. Nitric oxide is a hormone that helps to relax blood vessels and improve blood flow. Studies have shown that BTN2A3P is involved in the regulation of nitric oxide production by controlling the activity of a protein called nitric oxide synthase (NOS). NOS is a protein that is involved in the production of nitric oxide, and studies have shown that BTN2A3P is involved in the regulation of NOS activity by activating its activity.

Given the potential role of BTN2A3P in the regulation of blood pressure, it is an attractive drug target for treating hypertension. Studies have shown that BTN2A3P can be effectively targeted with small molecules, such as those that inhibit its activity or that activate its activity. In addition to its potential use as a drug target, BTN2A3P has also been shown to be a potential biomarker for measuring blood pressure.

TheBTN2A3P gene has been shown to be involved in the regulation of blood pressure by controlling the activity of the RAAS and the nervous system. Studies have shown that when BTN2A3P is activated, it inhibits the activity of the RAAS and reduces the production of angiotensin II. This has the potential to lower blood pressure and make it a potential drug target for treating hypertension. In addition, BTN2A3P has also been shown to be involved in the regulation of blood pressure by controlling the production of nitric oxide, which could be

Protein Name: Butyrophilin Subfamily 2 Member A3, Pseudogene

The "BTN2A3P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTN2A3P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets